Tritonix.ai

News / Taiwan / economic_daily

Taiwan Biotech Firms Joyful: Fortune and PharmaEssentia Report Record August Revenues

Health Technology · Biotechnology · economic_daily · 2026-09-08

Taiwanese biotech companies Fortune and PharmaEssentia posted record-breaking August revenues, driven by strong product sales and international market expansion.

What Happened

Fortune's Revenue Growth: Fortune reported an August revenue of NT$754 million, a nearly 50% year-over-year increase, marking a new record for the period. The growth was primarily fueled by robust sales in oncology, cardiovascular, and women's health products.

PharmaEssentia's Record Performance: PharmaEssentia achieved a record monthly revenue of NT$2.617 billion in August, representing a 105.4% year-over-year surge. This performance was bolstered by strong sales in the U.S. market and the steady distribution of its Ropeg injection pens.

Fortune's Global Expansion: Fortune is deepening its footprint in Asia, having recently secured distribution partnerships in Vietnam for products expected to launch in 2029. Additionally, the company's hormone facility passed a Japanese PMDA inspection, paving the way for future international market entry.

PharmaEssentia's Regulatory Milestones: PharmaEssentia's blood cancer drug Ropeg recently received approval for Essential Thrombocythemia (ET) in both Japan and the U.S. The company expects to benefit from a seven-year market exclusivity period in the U.S., significantly enhancing its long-term growth outlook.

Read original

More in Health Technology

Xufu August Revenue Soars 187.52% Year-over-Year

Health Technology · cnyes · 2026-09-08

Xufu (4119) reported August 2026 revenue of NT$149 million, a 187.52% year-over-year surge, with year-to-date revenue growth at 14.21%.

4119

AstraZeneca Reports Positive Late-Stage Data for Tozorakimab in COPD Treatment

Health Technology · cnbc · 2026-09-08

AstraZeneca's experimental COPD drug, tozorakimab, showed significant efficacy in late-stage trials, bolstering the company's multi-billion dollar sales outlook.

AZN, AZN, SNY, GSK, GILD, SNY, REGN, GSK, IBB

Lumosa Therapeutics August Revenue Skyrockets Over 5000% YoY

Health Technology · cnyes · 2026-09-08

Lumosa Therapeutics (6535) reported a massive 5,135.84% year-over-year revenue surge in August, with the stock outperforming the biotech sector index.

6535

Latest in Taiwan

CTBC Financial Subsidiaries Plan $127M Combined Bid for HanTest IPO

Electronic Technology · cnyes · 2026-09-08

CTBC Bank and Taiwan Life Insurance have announced plans to invest up to NT$4.1 billion in the upcoming IPO of semiconductor equipment firm HanTest.

2891, 7856

Eastek Hits Daily Limit Up at Open: What's Driving the Surge?

Electronic Technology · economic_daily · 2026-09-08

Eastek shares surged to the daily limit immediately upon opening today, drawing significant investor attention to the catalysts behind the sudden rally.

Guoqing Tech Surges to Limit Up on Heavy Volume

Electronic Technology · economic_daily · 2026-09-08

Guoqing Tech shares hit the daily limit at the open today amid a significant surge in trading volume, sparking speculation about potential positive news.

Foreign Investors Accumulate Taichung Bank, Driving Ex-Dividend Recovery

Finance · economic_daily · 2026-09-08

Taichung Bank is seeing strong buying interest from foreign institutional investors, fueling optimism for a swift recovery in its ex-dividend price.